Lyra Therapeutics (LYRA)
(Delayed Data from NSDQ)
$6.70 USD
-0.19 (-2.76%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $6.70 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LYRA 6.70 -0.19(-2.76%)
Will LYRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LYRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LYRA
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why
LYRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates
Other News for LYRA
Lyra Therapeutics registers shares for resale from warrant exercises
Lyra Therapeutics (LYRA) Proposes Sale of 846,744 Shares of Common Stock | LYRA Stock News
Lyra Therapeutics files to sell 846,744 shares of common stock for holders
12 Health Care Stocks Moving In Friday's Intraday Session
Lyra Therapeutics Secures $4.3M in Direct Offering